Research and Development

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered …

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …

ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to …

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …

GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative …

NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment …

BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …

Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …

Biopharma company Mirum Pharmaceuticals has announced data from its phase 3 MARCH-PFIC study which evaluated maralixibat in patients with progressive …

US RNA biomarker company Circular Genomics has announced study results highlighting the company’s first blood assay to predict a patient’s …

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …

Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …

AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The …

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …